International experience with the use of Cocoon septal occluder for closure of atrial septal defects.


Journal

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
ISSN: 2241-5955
Titre abrégé: Hellenic J Cardiol
Pays: Netherlands
ID NLM: 101257381

Informations de publication

Date de publication:
Historique:
received: 11 09 2020
revised: 14 12 2020
accepted: 17 12 2020
pubmed: 24 1 2021
medline: 19 8 2021
entrez: 23 1 2021
Statut: ppublish

Résumé

The Cocoon septal occluder (CSO) is a new generation double disk occluder device for catheter closure of the secundum atrial septal defect (ASD). Initial clinical evaluations with the use of this device have shown quite satisfactory results but large follow-up studies are missing. In this international multicenter study, we present procedural and follow-up data from 4008 patients with secundum ASD who underwent catheter closure with the use of CSO. The study cohort consisted of 1853 pediatric and 2155 adult patients with secundum ASD treated with the CSO. Patients were enrolled retrospectively from 11 international centers and were followed for a mean period of 43 months (range 12-84 months), postprocedural. Clinical, electrocardiographic, echocardiographic, procedural, and follow-up data were collected from each collaborating hospital. The CSO was permanently implanted in 3983 patients (99.4%). Echocardiographic evaluation at one month follow-up revealed complete closure in 99.6% of those patients who had a device implanted. Thrombus formation in one adult patient was the only major device related to procedural complication. During the follow-up period, no patient developed cardiac erosions, allergic reactions to nickel, or other major complications. Implantation of CSO provided satisfactory procedural and follow-up results with high success and no device-related cardiac erosions and nickel allergy.

Sections du résumé

BACKGROUND BACKGROUND
The Cocoon septal occluder (CSO) is a new generation double disk occluder device for catheter closure of the secundum atrial septal defect (ASD). Initial clinical evaluations with the use of this device have shown quite satisfactory results but large follow-up studies are missing. In this international multicenter study, we present procedural and follow-up data from 4008 patients with secundum ASD who underwent catheter closure with the use of CSO.
METHODS METHODS
The study cohort consisted of 1853 pediatric and 2155 adult patients with secundum ASD treated with the CSO. Patients were enrolled retrospectively from 11 international centers and were followed for a mean period of 43 months (range 12-84 months), postprocedural. Clinical, electrocardiographic, echocardiographic, procedural, and follow-up data were collected from each collaborating hospital.
RESULTS RESULTS
The CSO was permanently implanted in 3983 patients (99.4%). Echocardiographic evaluation at one month follow-up revealed complete closure in 99.6% of those patients who had a device implanted. Thrombus formation in one adult patient was the only major device related to procedural complication. During the follow-up period, no patient developed cardiac erosions, allergic reactions to nickel, or other major complications.
CONCLUSIONS CONCLUSIONS
Implantation of CSO provided satisfactory procedural and follow-up results with high success and no device-related cardiac erosions and nickel allergy.

Identifiants

pubmed: 33484876
pii: S1109-9666(20)30291-8
doi: 10.1016/j.hjc.2020.12.009
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

206-211

Informations de copyright

Copyright © 2021 Hellenic Society of Cardiology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interest None.

Auteurs

Basil Vasilios D Thanopoulos (BVD)

Department of Cardiology IASO Children's Hospital, Athens, Greece. Electronic address: vthanop@otenet.gr.

Lars Soendergaard (L)

Department of Cardiology Copenhagen University Hospital, Rigshospitalet, Denmark.

Hieu Lan Ngugen (HL)

Department of Cardiology Bach Mai Hospital, Hanoi, Viet Nam.

Maurizio Marasini (M)

Pediatric Cardiology Unit Giannina Gaslini Hospital, Genova, Italy.

Andreas Giannopoulos (A)

Department of Pediatric Cardiology AHEPA University General Hospital of Thessaloniki, Greece.

Georgios C Bompotis (GC)

Department of Cardiology Papageorgiou General Hospital of Thessaloniki, Greece.

Tasalac Thonghong (T)

Department of Cardiology Chiang Mai University Hospital, Chiang Mai, Thailand.

Kavassery Mahadevan Krishnamoorthy (KM)

Department of Cardiology Sree Chitra Tirunal Institute for Medical Sciences and Technology, Kerala, India.

Sebastian Placid (S)

Department of Cardiology Sakaharna Hrudayalaya Hospital, Kerala, India.

Dan Deleanou (D)

Institute for Cardiovascular Diseases C.C. Iliescu, Bucharest, Romania.

Konstantinos P Toutouzas (KP)

First Department of Cardiology Hippokration General Hospital, National and Kapodistrian University of Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH